To summarize the role of ferroptosis in the pathogenesis and treatment of myelodysplastic syndromes (MDS) and to discuss the potential of nanotechnology in enhancing ferroptosis-targeting therapies.
Approach:
Literature Review: Relevant studies were identified through major databases focusing on ferroptosis, iron metabolism, oxidative stress, and nanotechnology-based therapeutic approaches in MDS.
Key Findings:
MDS is characterized by ineffective hematopoiesis and systemic iron overload, leading to oxidative stress.
Ferroptosis plays a dual role in MDS: it can exacerbate ineffective hematopoiesis in lower-risk settings and may serve as a therapeutic target in higher-risk settings.
Current ferroptosis-targeting agents face limitations such as poor solubility, low stability, and potential toxicity to normal tissues.
Nanotechnology can enhance drug delivery and targeting to the bone marrow, potentially improving the efficacy of ferroptosis modulation.
Interpretation:
The dual role of ferroptosis in MDS presents both therapeutic opportunities and challenges, particularly in balancing efficacy against normal hematopoiesis.
Limitations:
Direct evidence on nanotechnology-mediated ferroptosis regulation in MDS is limited.
Current ferroptosis inducers have several limitations that need to be addressed.
Conclusion:
Nanotechnology may provide a strategy for precision treatment of MDS by improving the modulation of ferroptosis.
